Sign In
Buy EVAX
Evaxion Biotech A/S Earnings Calls
| Release date | May 07, 2026 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.440 |
| EPS Surprise | -4,300.00% |
| Revenue estimate | 9.2M |
| Revenue actual | - |
| Release date | Mar 05, 2026 |
| EPS estimate | -$0.245 |
| EPS actual | -$1.00 |
| EPS Surprise | -308.16% |
| Revenue estimate | 7.5M |
| Revenue actual | - |
| Release date | Nov 06, 2025 |
| EPS estimate | - |
| EPS actual | $0.730 |
| Revenue estimate | - |
| Revenue actual | 7.492M |
| Release date | Aug 14, 2025 |
| EPS estimate | -$0.500 |
| EPS actual | -$0.760 |
| EPS Surprise | -52.00% |
| Revenue estimate | 8M |
| Revenue actual | 37K |
| Revenue Surprise | -99.54% |
Last 4 Quarters for Evaxion Biotech A/S
Below you can see how EVAX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 14, 2025 |
| Price on release | $2.86 |
| EPS estimate | -$0.500 |
| EPS actual | -$0.760 |
| EPS surprise | -52.00% |
| Date | Price |
|---|---|
| Aug 08, 2025 | $2.83 |
| Aug 11, 2025 | $2.77 |
| Aug 12, 2025 | $2.85 |
| Aug 13, 2025 | $3.04 |
| Aug 14, 2025 | $2.86 |
| Aug 15, 2025 | $2.88 |
| Aug 18, 2025 | $3.22 |
| Aug 19, 2025 | $3.04 |
| Aug 20, 2025 | $2.95 |
| 4 days before | 1.06% |
| 4 days after | 3.15% |
| On release day | 0.699% |
| Change in period | 4.24% |
| Release date | Nov 06, 2025 |
| Price on release | $6.26 |
| EPS estimate | - |
| EPS actual | $0.730 |
| Date | Price |
|---|---|
| Oct 31, 2025 | $5.75 |
| Nov 03, 2025 | $5.77 |
| Nov 04, 2025 | $5.60 |
| Nov 05, 2025 | $5.66 |
| Nov 06, 2025 | $6.26 |
| Nov 07, 2025 | $6.38 |
| Nov 10, 2025 | $6.38 |
| Nov 11, 2025 | $6.00 |
| Nov 12, 2025 | $5.90 |
| 4 days before | 8.87% |
| 4 days after | -5.75% |
| On release day | 1.92% |
| Change in period | 2.61% |
| Release date | Mar 05, 2026 |
| Price on release | $3.40 |
| EPS estimate | -$0.245 |
| EPS actual | -$1.00 |
| EPS surprise | -308.16% |
| Date | Price |
|---|---|
| Feb 27, 2026 | $3.16 |
| Mar 02, 2026 | $3.17 |
| Mar 03, 2026 | $3.12 |
| Mar 04, 2026 | $3.11 |
| Mar 05, 2026 | $3.40 |
| Mar 06, 2026 | $3.22 |
| Mar 09, 2026 | $3.08 |
| Mar 10, 2026 | $3.58 |
| Mar 11, 2026 | $3.87 |
| 4 days before | 7.59% |
| 4 days after | 13.82% |
| On release day | -5.29% |
| Change in period | 22.47% |
| Release date | May 07, 2026 |
| Price on release | $4.07 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.440 |
| EPS surprise | -4,300.00% |
| Date | Price |
|---|---|
| May 01, 2026 | $4.50 |
| May 04, 2026 | $4.57 |
| May 05, 2026 | $4.40 |
| May 06, 2026 | $4.41 |
| May 07, 2026 | $4.07 |
| May 08, 2026 | $4.34 |
| May 11, 2026 | $4.23 |
| May 12, 2026 | $4.17 |
| May 13, 2026 | $4.16 |
| 4 days before | -9.45% |
| 4 days after | 2.21% |
| On release day | 6.63% |
| Change in period | -7.45% |
Evaxion Biotech A/S Earnings Call Transcript Summary of Q1 2026
Evaxion reported a productive Q1 2026 focused on advancing its AI-Immunology platform and clinical pipeline while conserving cash. Key R&D highlights include strong translational data from EVX-01 (personalized neoantigen peptide vaccine for advanced melanoma) with an 86% immunogenicity rate and 86% de novo T-cell responses presented at AACR, an upcoming 3-year clinical outcome update in H2 2026, and FDA Fast Track designation for EVX-01. Preclinical work showed the platform can design personalized vaccine candidates for glioblastoma (GBM) and was used with the Gates Foundation to design an improved polio antigen, underscoring broader applicability across oncology and infectious disease. Operationally, the company reorganized to sharpen external BD efforts, promoted Birgitte Rono to CSO and COO, and added BD expertise to the board (Jens Bitsch-Norhave). Financially, Evaxion projects ~USD 14M operational cash burn for 2026, ended Q1 with USD 18.4M cash/equivalents, and maintains runway into H2 2027 (assuming no new partnerships). The company is prioritizing strategic partnerships for both personalized oncology assets (EVX-01/EVX-03) and select infectious disease programs, and aims for clinical readiness for its off-the-shelf AML program EVX-04 by year-end.
